Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2759803 | 1.00 | MDM2 (0.75) | MDM2TP53 | |
| SCHEMBL2133492 | 0.98 | MDM2 (0.78) | MDM2TP53 | |
| SCHEMBL2624259 | 0.94 | MDM2 (0.67) | MDM2TP53 | |
| SCHEMBL2128907 | 0.94 | MDM2 (0.79) | MDM2TP53 | |
| SCHEMBL2624231 | 0.94 | MDM2 (0.79) | MDM2TP53 | |
| SCHEMBL2953141 | 0.90 | MDM2 (0.61) | MDM2TP53 | |
| SCHEMBL251227 | 0.90 | MDM2 (0.61) | MDM2TP53 | |
| SCHEMBL249208 | 0.89 | MDM2 (0.64) | MDM2TP53 | |
| SCHEMBL2129544 | 0.89 | MDM2 (0.77) | MDM2TP53 | |
| SCHEMBL2624248 | 0.89 | MDM2 (0.77) | MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901117-B2 | Small molecule inhibitors of MDM2 and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-12-02 | — | — | US | disclosed |
| US-8742121-B2 | Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120101092-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101092-A1 | SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | TP53, MDM2, CDKN1A | MDM2 2/4885TP53 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.